Insights

Gathering insights about Entrepreneur…

Similar companies to Entrepreneur

Entrepreneur Tech Stack

Entrepreneur uses 6 technology products and services including Cloudflare, Svelte, Vercel, and more. Explore Entrepreneur's tech stack below.

Cloudflare
Content Management System
Svelte
Javascript Frameworks
Vercel
Platform As A Service
HSTS
Security
Tailwind CSS
UI Frameworks
Nginx
Web Servers

Media & News

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. “ELEVATE-45-201 is the most advanced clinical study of a conjugated exon skipping therapy for individuals amenable to exon 45 skipping and offers the potential to address a large Duchenne subpopulation with significant unmet medical needs,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
May 28, 2025 | www.globenewswire.com
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 45 skipping.
Mar 24, 2025 | www.globenewswire.com
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. The global ELEVATE-44 program, which includes the ELEVATE-44-102 study in the U.S. and ELEVATE-44-201 outside of the U.S., will cover a broad population of patients with DMD and support evaluation of ENTR-601-44 in patients with both early and advanced disease.
Feb 24, 2025 | www.globenewswire.com
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. “The clearance by the MHRA marks a new phase in Entrada's growth and, most importantly, moves us closer to realizing our commitment to families living with Duchenne muscular dystrophy,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
Feb 03, 2025 | www.globenewswire.com
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments –
Jun 24, 2024 | www.globenewswire.com
This Week in ETFs: 7 New ETFs Dwarfed by 11 Closures
During the past week, in the wake of the Exchange conference, launches of new ETFs started to pick up again from their recent lull. A total of seven funds rolled out during the week, while several issuers announced or completed ETF closures.
Feb 23, 2024 | www.etftrends.com
ETF of the Week: ERShares Entrepreneurs ETF (ENTR)
VettaFi's vice chairman Tom Lydon discussed the ERShares Entrepreneurs ETF (ENTR) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” Entrepreneurial companies are on fire, positioning the ERShares Entrepreneurs ETF (ENTR) among the rising ETFs.
Apr 06, 2023 | www.etftrends.com

Entrepreneur's Email Address Formats

Entrepreneur uses at least 1 format(s):

Entrepreneur Email Formats	Example	Percentage
First.Last@briancray.com	John.Doe@briancray.com	50%
First.Last@briancray.com	John.Doe@briancray.com	50%

Frequently Asked Questions

Where is Entrepreneur's headquarters located?

Entrepreneur's main headquarters is located at 43228 United States. The company has employees across 6 continents, including North AmericaAsiaEurope.

What is Entrepreneur's stock symbol?

Entrepreneur is a publicly traded company; the company's stock symbol is ENTR.

What is Entrepreneur's official website and social media links?

Entrepreneur's official website is briancray.com and has social profiles on LinkedIn.

What is Entrepreneur's NAICS code?

Entrepreneur's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Entrepreneur have currently?

As of August 2025, Entrepreneur has approximately 1 employees across 6 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: L. M.Chief Executive Officer: L. M.CEO Of Triumph Tutoring And Lifestyle Services: S. B.. Explore Entrepreneur's employee directory with LeadIQ.

What industry does Entrepreneur belong to?

Entrepreneur operates in the Technology, Information and Internet industry.

What technology does Entrepreneur use?

Entrepreneur's tech stack includes CloudflareSvelteVercelHSTSTailwind CSSNginx.

What is Entrepreneur's email format?

Entrepreneur's email format typically follows the pattern of First.Last@briancray.com. Find more Entrepreneur email formats with LeadIQ.

Entrepreneur

Q: What is Entrepreneur's official website and social media links?

Entrepreneur's official website is briancray.com. Entrepreneur has social profiles on LinkedIn.

Q: How many employees does Entrepreneur have currently?

Entrepreneur has approximately 1 employees.

Q: What technology does Entrepreneur use?

Entrepreneur's tech stack includes Svelte, Vercel, Cloudflare, Tailwind CSS, Nginx.

Technology, Information and InternetUnited States0-1 Employees

Brian Cray writes a blog that helps web 2.0 professionals build better websites, develops websites that make people happy, and adds value to business with website services.